GSK falls in line with Big Pharma's reaction to Ukraine invasion, cutting off new clinical trials, donating profits and more
Just a few days after multiple Big Pharmas such as Bayer and Pfizer started the de-facto Big Pharma response to Russian aggression in Ukraine, other global players such as Novartis and Eli Lilly started to follow suit, pushing beyond its first tentative steps with a full-throated commitment to severing business ties with Russia wherever possible.
Now another one of the handful of holdouts is piling on: London-based GlaxoSmithKline. The pharma — helmed by Emma Walmsley — announced overnight that the company has taken a few actions in Russia, saying:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.